China investigation

Our China business has been investigated by authorities in the country over allegations of fraudulent behaviour. We have been deeply concerned and disappointed by these allegations. Such behaviour is a clear breach of our systems, governance procedures, values and standards.

We take this matter very seriously and have been co-operating fully with the Chinese authorities. GSK has zero tolerance for any behaviour of this nature.

GSK China investigation outcome - press release

Statement of Apology (PDF)

You can find out more information about our compliance procedures in our Responsible Business Supplement.

Our commitment to China

China is an important market for GSK – we sell medicines, vaccines and consumer products in the country.

We have invested heavily in China, spending more than US$500 million to date, creating more than 7,000 jobs and running a number of factories.

We also have a major research and development centre in China, which is the global centre for our research into neurodegenerative diseases such as Alzheimer's disease.

GSK remains committed to China for the long term to serve customers, partners and patients.